Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands

Abstract

Background

Cladribine tablets have recently become available in The Netherlands for patients with relapsing–remitting multiple sclerosis (RRMS) as a disease-modifying agent that reduces the frequency and severity of relapses and delays disability progression.

Objective

The aim of this study was to evaluate the cost effectiveness of cladribine tablets, compared with alternative options, in the treatment of RRMS patients with high disease activity (HDA) and patients with rapidly evolving severe (RES) MS in The Netherlands.

Methods

A Markov model was developed simulating the costs and effects of RRMS treatment. For HDA, alemtuzumab and fingolimod were used as comparators; natalizumab was used for the RES subpopulation. The analysis included a societal perspective and a value-of-information (VOI) analysis.

Results

For the HDA subpopulation, treatment with cladribine tablets was the cost-effective (dominant) strategy compared with alemtuzumab and fingolimod, with 50.9% and 98.2%, respectively, probability of being cost effective at a threshold of €50,000/QALY gained and a net monetary benefit (NMB) of €10,866 and €151,115, respectively. For the RES subpopulation, treatment with cladribine tablets dominated treatment with natalizumab, with 94.1% probability of being cost effective at a threshold of €50,000/QALY gained and an NMB of €122,986. Note that these outcomes are driven by the lower costs of cladribine tablets. Efficacy differences were small, very uncertain, and likely not clinically meaningful. The probabilistic sensitivity analyses showed significant overlap in the credible intervals for total lifetime QALY outcomes and costs of cladribine tablets and all relevant comparators. The population-level VOI amounted to €19,295,441.

Conclusions

The base-case analysis shows that treatment of RRMS with cladribine tablets is cost effective versus alemtuzumab and fingolimod in HDA patients, and cost effective versus natalizumab in RES patients, at a threshold of €50,000. Driven by the lower costs, cladribine tablets were cost effective (dominant) in all base-case analyses. However, given that outcomes are based on indirect comparisons and post hoc subgroup analysis, as well as the uncertainty surrounding the outcomes, the results presented in this paper should be interpreted with caution.

Electronic supplementary material

The online version of this article (10.1007/s40258-019-00500-8) contains supplementary material, which is available to authorized users.

Key Points for Decision Makers

This model is the first example of assessing the cost effectiveness of cladribine tablets versus other disease-modifying drugs (DMDs) in the treatment of patients with relapse-remitting multiple sclerosis (RRMS) in The Netherlands.

The model allowed for analysis from a full societal perspective, including indirect medical costs, productivity costs, and costs for informal care.

Cladribine tablets were estimated to be a cost-effective treatment for patients with RRMS and high disease activity/rapidly evolving severe disease compared with the current standard of care in The Netherlands.

These analyses show drug costs are the main driver of differences in cost effectiveness between treatments.

Given that outcomes are based on indirect comparisons and post hoc subgroup analysis, as well as the uncertainty surrounding the outcomes, the results presented in this paper should be interpreted with caution.

Introduction

Multiple sclerosis (MS) is a chronic and degenerative neurological condition that is associated with neurological impairment, severe disability, and premature mortality [1]. In a population-based study specific to The Netherlands, the overall age-sex standardized incidence rate of MS was 4.8/100,000 person-years and prevalence was estimated to be 1 in 1000 patients [2]. Most patients will experience the initial symptoms of disease upon diagnosis during early adulthood; the symptoms can progress rapidly and approximately 50% of patients will eventually require assistance to walk and will be confined to a wheelchair or bed. Since there are currently no curative interventions, the condition will persist throughout the life of the person with MS [3].

There are two broad categories for MS—relapsing disease and progressive disease. Relapsing disease is categorized in clinically isolated syndrome (CIS) and relapsing–remitting multiple sclerosis (RRMS), whereas progressive disease is categorized in progressive accumulation of disability from onset (primary progressive; PP) and progressive accumulation of disability after initial relapsing course (secondary progressive; SP) [4]. The relapsing phase is characterized by the occurrence of relapses that have a tendency over time to remit. Relapses may result in an increase in disability because remittance is not always complete, depending on the period of remission [5, 6]. On average, relapses occur once or twice a year and are associated with inflammation and the development of new focal lesions. Over time, approximately 90% of patients with RRMS will develop SPMS, which is characterized by fewer relapse events and a gradual progression in disability between relapses [7]. The RRMS phenotype is of primary interest for this article, with special focus on high disease activity (HDA) and rapidly evolving severe (RES) subpopulations.

Progression to advanced stages of the disease has a significant impact on the health-related quality of life (HRQoL) of patients and their caregivers, and can lead to a significant cost burden to payers and society [1, 2, 8]. Available Dutch MS guidelines [9] advise a multidisciplinary approach to care, including support from neurologists, MS nurses, and therapists. This supportive care is provided alongside pharmacological therapy, which includes the treatment of symptoms of disability progression and the use of disease-modifying drugs (DMDs) [10]. The goal of therapy with DMDs is to reduce the frequency and severity of relapse events and to delay disability progression. There are currently 11 approved DMDs for MS. At the time of model adaptation, the most recently approved products currently reimbursed in The Netherlands for the treatment of RRMS with HDA/RES were alemtuzumab, fingolimod, and natalizumab [9].

Cladribine tablets (Mavenclad^®) are an oral DMD approved by the European Medicines Agency (EMA) in August 2017. Cladribine is a preferential lymphocyte-depleting therapy that has a unique posology involving only two short treatment courses over a 2-year period, followed by at least 2 years of disease monitoring. The results of the phase III trials, CLARITY and CLARITY EXT (RRMS), demonstrate that treatment with cladribine tablets is associated with a significant reduction in the annualized relapse rate (ARR), an increase in the proportion free of relapse, and a significant reduction in the risk of 3- and 6-month EDSS progression compared with patients treated with placebo [11, 12]. While the cost effectiveness of cladribine tablets versus existing DMDs for RRMS has been assessed for the UK [13], no such study has been conducted for The Netherlands. The aim of this study was to evaluate the cost effectiveness of cladribine tablets compared with alemtuzumab and fingolimod for patients with RRMS and HDA, and compared with natalizumab for patients with RES RRMS in The Netherlands.1 This is the first time a societal perspective has also been included in a cost-effectiveness evaluation of cladribine tablets.

Methods

To meet the aim of this study, a previously constructed health economic model [13] was adapted to meet the requirements of the Dutch Healthcare Institute and to reflect Dutch clinical practice, meaning that Dutch HRQoL and cost inputs were implemented, and some structural changes were made to include indirect non-medical and medical costs, as well as direct non-medical costs and a value of information (VOI) analysis. Model inputs were validated by means of a face-to-face expert with a Dutch key opinion leader (KOL) in MS treatment.

Study Population and Comparators

Given the approved indication for treatment with cladribine tablets, the population of interest was patients with RRMS and HDA. The relevant comparators in The Netherlands that were included in the analyses were fingolimod, alemtuzumab, and natalizumab as these three DMDs are specifically used in The Netherlands for the treatment of RRMS with HDA/RES [14]. These comparators were also validated by a clinical KOL. Data for RRMS patients with HDA were not available for all comparators included in the analysis (natalizumab); therefore, the RES RRMS subpopulation was also considered in this study as natalizumab is only used in the RES population in The Netherlands.

Baseline characteristics in the model were obtained from the placebo arm of the CLARITY phase III study (Table 1). The relevance of these characteristics for the Dutch patient population was confirmed by a Dutch KOL with experience in MS.

Table 1.

Baseline characteristics of the study populations in the model (CLARITY study)

Characteristic	HDA population	RES population
Mean age at treatment, (years)	37.1	33.3
Standard error	0.836	1.281
Female to male ratio	1.709	1.412
Number of relapses in the prior year	2.020	2.244
Average patient weight, (kg)	69.72	69.29
Weight distribution, kg (%)
40–50	6.2	9.9
50–60	21.5	17.6
60–70	29.4	34.1
70–80	20.4	15.4
80–90	10.0	8.8
90–100	6.9	8.8
100–110	3.5	4.4
> 110 kg	2.1	1.1
Distribution over EDSS states (%)
EDSS 0	2.8	4.4
EDSS 1.0	2.8	3.3
EDSS 2.0	32.5	31.9
EDSS 3.0	21.5	20.9
EDSS 4.0	23.5	23.1
EDSS 5.0	11.1	11.0
EDSS 6.0	5.9	5.5
EDSS 7.0	0.0	0.0
EDSS 8.0	0.0	0.0
EDSS 9.0	0.0	0.0
Sample (n)	289	91
References	Giovannoni et al. [32]	Giovannoni et al. [32]

HDA high disease activity, RES rapidly evolving severe, EDSS Expanded Disability Status Scale

Model Structure

A cohort-based multi-state Markov transition model was developed in Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) to simulate the costs and effectiveness of treatment in people with RRMS [13]. This model was based on two mathematical models—a natural history reference model, developed using data on the disability progression and relapse status of people receiving best supportive care (BSC), and a treatment-adjusted model, which combines the reference model with data on the comparative efficacy and safety of the various DMDs versus placebo. The natural history model has data for generic RRMS, whereas the treatment-adjusted model incorporates the distinction between HDA and RES. Disease progression was modeled using the Kurtzke Expanded Disability Status Scale (EDSS) system, presented in a 21-health-state structure comprising 10 EDSS states for RRMS, 10 EDSS states for SPMS, and 1 death state (general mortality). This is an established disability rating scale that ranges from 0 (normal health) to 10 (death due to MS), where increasing scores indicate greater clinical disability [15]. The scale measures a range of functional issues, including bowel and bladder function, visual function, and mobility, and is the primary instrument used to evaluate the clinical disability of people with MS. The model explicitly accounts for differences in the disability progression rate and quality of life between the RRMS and SPMS phases. The 21-health-state structure is based on the assessment group model developed for the National Institute for Health and Care Excellence (NICE) TA32 [16], a multiple technology appraisal of β-interferon and glatiramer acetate in RRMS [16] (an illustration of the 21-health-state structure is provided in Fig. 1). The model structure was validated by the Dutch KOL, who indicated that it was appropriate to differentiate between progression rates in RRMS and SPMS.

Fig. 1.

Health state structure of the 21-state model including periods on and off DMDs

At the start of the evaluation, the patient cohort is proportionally assigned to the 10 RRMS EDSS states in the model, according to the baseline EDSS distribution in the CLARITY study (Table 1). Over time, the cohort is at risk of experiencing disability progression (move to a higher EDSS state), improving disability status (move to a lower EDSS state), remaining at their current level of disability (remain in their current EDSS state), converting to SPMS, or dying. Progression to SPMS is associated with a 1-point increase in EDSS. Please note that there has been some debate by the NICE Evidence Review Group on this point, however previous NICE appraisals deemed the assumption of a 1-point increase in EDSS to be an appropriate reflection if increasing disability experiences upon progression to an SPMS disease course (for instance, see page 10 of NICE TA493 [52]). The treatment-adjusted model was created by combining the natural history reference model with the comparative efficacy and safety of DMDs versus placebo. Treatment with a DMD is assumed to impact the following outcomes: decrease the probability of progressing in an EDSS state over time, decrease the annualized rate of relapse, and increase or decrease the incidence of drug-related adverse events. In each model cycle, patients taking DMDs were at risk of discontinuing treatment from loss of efficacy, loss of tolerability, progression to EDSS ≥ 7.0, or development of SPMS. This is in line with the recommendations of the Association of British Neurologists advising clinicians when they should consider stopping treatment. It was assumed that any patient transitioning to an EDSS state ≥ 7.0 would be considered to have SPMS, and hence discontinued from therapy. This is in line with approaches taken in previous models [13].

As is required by Dutch health economic guidelines published by the Dutch Healthcare Institute [17], the model takes a societal perspective. In addition to direct medical costs, the model considers productivity loss, informal care, and unrelated medical costs. Given the chronic nature of MS, a time horizon of 50 years (close to a lifetime) was used and the cycle length was set to 1 year, representing enough time to observe changes in RRMS disease progression and corresponding with time points of clinical studies of interest. Half-cycle correction2 was performed and annual discount rates of 4% and 1.5% were applied to costs and outcomes, respectively [17]. Outcomes measured as cost per incremental QALY were compared with the reference values set out by the Dutch Healthcare Institute to determine whether an intervention was considered cost effective. The Healthcare Institute considers a willingness to pay (WTP) reference value of either €20,000/QALY (for treatment of illnesses with a low disease severity), €50,000/QALY (medium disease severity), or €80,000/QALY (for high disease severity) [18]. Although the disease severity of RRMS with HDA can be considered high, the more conservative €50,000/QALY was applied as the reference value.

Model Inputs

Clinical

The model included clinical inputs for EDSS transition, conversion to SPMS, relapse rate, mortality rate, and inputs related to treatment, such as comparative efficacy, waning effect, adverse events, and probability of discontinuation. The treatment effect was based on post hoc subgroup analysis. The effect for each DMD derived from a network meta-analysis conducted on aggregated clinical trial data identified from a systematic literature review [19] (see Table 2). In addition, a meta regression analysis was conducted, extrapolating the effect size estimates from the active RRMS population to the RES group by relating efficacy to baseline risk and centering baseline risk to the expected value in each group [20].

Table 2.

Efficacy risk ratios for cladribine tablets versus comparators, from the network meta-analyses [19]

Annualized relapse rate
Cladribine tablets vs.	RR (95% CrI)
Alemtuzumab 12 mg qd	1.30 (0.93–1.83)
Fingolimod 0.5 mg qd	0.91 (0.67–1.22)
Natalizumab 300 mg q4w	1.22 (0.89–1.68)

Confirmed disease progression sustained for 6 months at 24 monthsa
Cladribine tablets vs.	HR (95% CrI)
Alemtuzumab 12 mg qd	1.37 (0.58–3.32)
Fingolimod 0.5 mg qd	0.79 (0.37–1.64)
Natalizumab 300 mg q4w	1.21 (0.52–2.77)

RR relapse rate, CrI credible interval, HR hazard ratio, qd once daily, q4w every 4 weeks

^aConfirmed disease progression measures the increase in a patient’s disease progression over a predetermined time period, in this case 6 months

For the natural history model, movement between the RRMS EDSS states was taken from the British Columbia Multiple Sclerosis (BCMS) registry [21] (Table 3). For conversion from RRMS to SPMS, data from the study by Koch et al., which reported the natural history of SPMS, were used [22]. In their study, Kock et al. report the results of a retrospective Kaplan–Meier and Cox regression analysis of the time to and age at SPMS in untreated people registered in the BCMS dataset. The generalized gamma was selected as the preferred survival function for the model because of its goodness of fit for data for both men and women. Due to the lack of data, the same SPMS conversion rates were assumed to apply across all HDA and RES populations. Progression rates within the SPMS states were taken from the London Ontario registry [23].

Table 3.

Annual transition probabilities (RRMS age of onset ≥ 28 years, and SMPS)

	From/to	0	1	2	3	4	5	6	7	8	9	Sample size
RRMS (EDSS score)	0	69.5	20.3	7.3	2.2	0.4	0.1	0.2	0.0	0.0	0.0	326
	1	5.8	69.5	15.8	6.1	1.6	0.5	0.6	0.0	0.0	0.0	317
	2	1.6	12.1	60.8	16.8	4.5	1.8	2.2	0.2	0.1	0.0	317
	3	0.6	5.0	12.0	54.4	9.1	5.8	11.6	1.0	0.4	0.0	317
	4	0.2	2.2	6.7	11.5	48.9	10.4	16.8	2.6	0.7	0.1	317
	5	0.1	0.5	2.9	5.9	8.7	48.7	27.3	3.9	1.9	0.1	317
	6	0.0	0.1	0.4	2.5	3.1	4.1	74.1	10.9	4.4	0.4	317
	7	0.0	0.0	0.1	0.2	0.7	0.4	11.7	69.3	16.1	1.6	317
	8	0.0	0.0	0.0	0.0	0.1	0.1	1.9	5.6	90.3	2.1	317
	9	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.6	17.4	81.8	317
SPMS (EDSS score)	0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	1	0.0	100.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	2	0.0	0.0	74.4	18.7	2.1	2.8	1.8	0.1	0.1	0.0	8
	3	0.0	0.0	0.0	70.4	15.9	3.1	9.6	0.5	0.4	0.0	85
	4	0.0	0.0	0.0	0.0	66.4	13.8	18.1	0.9	0.9	0.0	94
	5	0.0	0.0	0.0	0.0	0.0	57.4	37.4	2.6	2.6	0.0	91
	6	0.0	0.0	0.0	0.0	0.0	0.0	87.4	4.8	7.7	0.0	331
	7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	76.1	23.5	0.4	125
	8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	99.6	0.4	271
	9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	100.0	15

Data are expressed as percentages

RRMS relapse-remitting multiple sclerosis, EDSS Expanded Disability Status Scale, SPMS secondary progressive multiple sclerosis

The relapse rate was modeled independently of the EDSS state as studies show that these can occur separately from EDSS progression [24, 25]. Relapse events are calculated by applying an ARR to the number of patients alive in the model. The ARR is not constant but rather caries over time based on a proportional annual reduction (5.07%) calculated from data reported by Tremlett et al. [26, 27]. The baseline relapse rate is based on the rate observed in the placebo arm of the CLARITY study and is population-specific. Given that there was no notable difference between the relapse rate of patients treated with alemtuzumab or cladribine tablets, the ARR of alemtuzumab was set equal to cladribine tablets in the HDA population. This assumption is based on the fact that at the time of submission of both the model and the paper, no possible link was available for the ARR in HDA for alemtuzumab, but a possible link was available for natalizumab and fingolimod. The mortality rate is modeled to vary over time in line with aging of the cohort, and is estimated using all-cause sex- and age-matched mortality statistics that are inflated to account for the higher mortality rate associated with MS [28, 29].

The waning effect reflects the uncertainty in the longer-term benefits of drug therapy. It is assumed that the full effect of cladribine tablets is sustained through years 0–2, is assumed to wane from 100 to 75% in years 2–3, and is assumed to reach 50% from years 4–5 onwards. No further waning is assumed after year 5. The same waning effects are assumed for the comparators. The waning effects used in this analysis are aligned with those submitted and approved by the NICE in England [13].

The DMD-treated cohort is also at risk of discontinuing treatment. Patients discontinue treatment if the DMD does not reduce the frequency or severity of relapses compared with the pretreatment phase, if patients have intolerable adverse effects of the drug, if patients develop an inability to walk (EDSS 6.5–7.0), or if a patient develops SPMS. The annual probabilities of discontinuing treatment were taken from pooled trial data [18]. As guided by input from the KOL, following discontinuation of the drug it is assumed that treatment will consist of BSC, which is aimed at providing temporary relief from the disease (e.g. pain killers) but does not change the course of the disease. Furthermore, patients are at risk of discontinuation from treatment with cladribine and alemtuzumab between the first and second courses. Overall, 4.9% of patients receiving their first course of cladribine tablets and 2.3% of patients receiving their first course of alemtuzumab are assumed to discontinue before their second course (in year 2). Patients are subsequently assumed to be ‘taking DMDs’ until they discontinue due to EDSS progression or development of SPMS. Re-initiation is modeled for alemtuzumab (28% in year 3, 11% in year 4, 1% in year 5). Drug-related adverse events were included in the model, including infusion site reactions, injection site reactions, progressive multifocal leukoencephalopathy (PML), macular oedema, malignancy, hypersensitivity, gastrointestinal disorder, autoimmune thyroid-related events, immune thrombocytopenic purpura, severe infections, and influenza-like symptoms. The list of adverse events was developed following a review of the product characteristics for each drug included in the model, and confirmed by an external advisory panel comprising expert clinicians [30].

Utilities

Dutch EQ-5D-3L values for cladribine tablets were derived from the EQ-5D data collected in the CLARITY and CLARITY EXT studies using a Dutch preference set [31]. A systematic literature review was undertaken to identify relevant utility values, alongside the EQ-5D data collected in the CLARITY and CLARITY EXT studies [11, 12]. The model included the impact of disability progression, relapses, and drug-related adverse events on the HRQoL of patients. Additionally, it included the impact of disability on the HRQoL of the caregiver, given the societal perspective as required by the Dutch guidelines for health economic evaluations. A summary of the health state utilities in the base-case model is shown in Table 4.

Table 4.

Summary of health state utilities

Health state	(Dis)utilities (SE)	References
Relapse event	−0.071 (0.013)	[25]
Patient health utility
EDSS
0	0.917 (0.021)	[32]
1	0.856 (0.044)	[32]
2	0.816 (0.011)	[32]
3	0.729 (0.011)	[32]
4	0.697 (0.011)	[32]
5	0.623 (0.023)	[32]
6	0.548 (0.548)	[33]
7	0.422 (0.422)	[33]
8	0.234 (0.234)	[33]
9	0.005 (0.005)	[33]
SPMS conversion	0.045 (0.021)	[25]
Caregiver disutility
EDSS
0	− 0.002 (0.053)	[34]
1	− 0.002 (0.053)	[34]
2	− 0.002 (0.053)	[34]
3	− 0.045 (0.057)	[34]
4	− 0.142 (0.062)	[34]
5	− 0.160 (0.055)	[34]
6	− 0.173 (0.054)	[34]
7	− 0.030 (0.038)	[34]
8	− 0.095 (0.075)	[34]
9	− 0.095 (0.075)	[34]
Adverse events
Infusion site reaction	− 0.011 (0.002)	[35]
Injection site reaction	− 0.011 (0.002)	[35]
PML	− 0.200 (0.040)	[36]
Severe infection	− 0.190 (0.038)	[37]
Macular oedema	− 0.040 (0.008)	[36]
Gastrointestinal	− 0.240 (0.048)	[36]
Hypersensitivity	− 0.250 (0.050)	[36]
Autoimmune thyroid-related event	− 0.110 (0.022)	[36]
Influenza-like symptoms	− 0.210 (0.042)	[35]
Malignancy	− 0.116 (0.023)	[38]
Immune thrombocytopenia purpura	− 0.090 (0.018)	[36]

Health state utilities are sampled from a log-normal distribution, and the disutility values are sampled from a normal distribution

EDSS Expanded Disability Status Scale, SE standard error, PML progressive multifocal leukoencephalopathy, SPMS secondary progressive multiple sclerosis

Costs

The costs of acquisition, administration, and monitoring were assumed to apply for the duration of time that patients remain on therapy in the model (Tables 5, 6, 7). For continuously administered therapies, such as natalizumab or fingolimod, the number of people receiving therapy is estimated from the EDSS status of the population, considering those who discontinue (e.g. develop SPMS or discontinue for other reasons) in the previous cycle. All patients were assumed to adhere to therapy and consume the full course of medication in each year. The cost inputs were based on the Dutch costing manual [39], price lists, and Opendisdata [40]. Additional information came from a systematic review of cost studies, additional literature searches, and input from the Dutch KOL in case of unavailable information. For fixed-course therapies, such as alemtuzumab and cladribine tablets, drug costs were estimated based on the proportion of patients eligible for therapy (EDSS < 7.0 and RRMS) at the start of each cycle multiplied by the proportion treated. The annual drug costs were based on the Dutch list prices, obtained from the Z-index G-Standard of October 2017 [41]. All cost inputs were converted to 2016 costs.

Table 5.

Drug acquisition costs

Therapy	Pack	Unit per pack	Unit cost	Dose	Unit consumed per year 1/year 2	Total cost year 1 (€)	Total cost year 2 + a (€)	References
Cladribine tablets	1 × 10 mg tablet	1	€2785.71	0.875 mg/kg/dosea	12/12	33,780	33,780	[41]
Alemtuzumab	12 mg vial	1	€7000.00	12 mg/day	5/3	35,000	21,000
Fingolimod	28 capsules	28	€1695.12	1 tablet/day	365.25	22,112	22,112
Natalizumab	15 ml vial	1	€1594.35	300 mg every month	13	20,727	20,727

^aCosts for cladribine tablets were for years 1 and 2 only; no additional costs in years 3 and 4 during treatment

Table 6.

Drug administration costs

Therapy	Administration	Administration resources consumed per year of therapy	Total cost year 1 (€)	Total cost year 2 + (€)	References
Cladribine tablets	Oral	No administration requirements	0	0	[39]
Alemtuzumab	Infusion	5 × day-case admissions in the first year, plus three 1 g vials of methylprednisolone, one pack of paracetamol, two packs of acyclovir (200 mg), and five tablets of clemastin; 3 × day-case admissions in subsequent years, plus three 1 g vials of methylprednisolone, one pack of paracetamol, two packs of acyclovir (200 mg), and five tablets of clemastin	1507	950
Fingolimod	Oral	Day-case admission in the first year to monitor ECG	278.49	0
Natalizumab	Infusion	Monthly day-case admissions (13 in total)	3620	3620

ECG electrocardiagram

Table 7.

Drug monitoring costs

Therapy	Monitoring resources consumed in the first year	Monitoring resources consumed in subsequent years	Total cost year 1 (€)	Total cost year 2 + (€)	References
Cladribine tablets	1 × MRI scan 3 × complete blood counts (at months 2, 6, and 12) 2 × neurology visits	2 × complete blood counts (at months 14 and 18) 2 × neurology visits + 1 × MRI scan	418	415	[39, 40]
Alemtuzumab	12 × complete blood counts + 1 x MRI scan 12 × biochemistry tests for serum creatinine levels 12 × urinalysis tests with microscopy 4 × thyroid function tests (thyroid-stimulating hormone level) 1 × tuberculin skin test 0.65 × human papilloma virus test (females only – assumption 65%) 2 × neurology visits	12 × complete blood counts 12 × biochemistry tests for serum creatinine levels 12 × urinalysis tests with microscopy 4 × thyroid function tests (thyroid-stimulating hormone level) + 1 × MRI scan 0.65 × human papilloma virus test (females only − assumption 65%) 2 × neurology visits	788	770
Fingolimod	6 × complete blood counts (at months 1, 2, 3, 6, 9, and 12) 6 × biochemistry tests (months 0, 1, 3, 6, 9, and 12) 1 × Ophthalmology assessment 2 × neurology visits + 1 × MRI scan 1 × day-case admission (risk of heart attack) 1 × ECG procedure	2 × complete blood counts (every 6 months) 2 × biochemistry tests 2 × neurology visits 1 × MRI scan	955	440
Natalizumab	1 × JC virus test 2 × biochemistry test 1 × MRI scan 2 × neurologist visits	2 × JC virus tests (6-monthly) 2 × biochemistry tests 1 × MRI scan 2 × neurology visits	458	483

MRI magnetic resonance imaging, ECG electrocardiogram, JC John Cunningham’s virus testing

EDSS-related direct medical and non-medical costs, as well as indirect non-medical costs (presented in Table 8), were extracted from the paper from Karampampa et al. [42] and inflated to reflect 2017 values. Indirect unrelated medical costs (medical costs occurring during a lifetime that were unrelated to MS) were calculated by applying the Dutch PAID toolkit version 1.1, which enables the incorporation of future unrelated costs [43].

Table 8.

Costs by health state

Health state	Direct medical costs (€) [35]	Direct non-medical costs (€) [35]	Indirect non-medical costs (€) [35]
EDSS
0	12,071	5301	15,754
1	12,071	5301	15,754
2	12,071	5301	15,754
3	12,071	5301	15,754
4	14,634	16,025	24,006
5	14,634	16,025	24,006
6	14,634	16,025	24,006
7	14,634	16,025	24,006
8	14,966	56,001	36,605
9	14,966	56,001	36,605

EDSS Expanded Disability Status Scale

The costs associated with severe infections, macular edema, gastrointestinal disorder, hypersensitivity reaction, and autoimmune thyroid-related events are available from Opendisdata, a public database including data on average prices paid for healthcare products provided in Dutch hospitals [44]. The costs of infusion-based events are set to zero on the basis that these events would be managed in the day-case setting by delaying or slowing down the infusion rate or through low-cost pain intervention. The cost of these events would therefore be largely covered by the day-case admission. The management of injection site reactions and influenza-like illness are assumed to involve a phone consultation with a district nurse [36]. The average cost of an episode of immune thrombocytopenic purpura (grade III and IV) was obtained from the work of Blommestein et al., assuming the mean duration of an episode was 45 days [45].

The cost for relapses was estimated at €1024. It was assumed that during relapses, patients visited a neurologist, including 3-day admissions plus administration of methylprednisolone 1 g. These assumptions were validated by the KOL.

Sensitivity Analysis

DSAs were performed to evaluate the impact of uncertainty on the model outcomes, and were performed on the following variables: effect of DMDs on EDSS progression and relapse rate, discontinuation rates, mortality multiplier, baseline characteristics (age, weight), and discounting rates. The effect of DMDs on EDSS progression and relapse rates varied according to the Network meta-analysis (NMA) [18]. The range of variation used in the DSA was 50% for discontinuation probabilities, baseline sex ratio, and baseline relapse rate in the previous year. Discounting rates varied between 0 and 6%, and baseline characteristics varied using the standard error as provided in the CLARITY study.

In addition, structural sensitivity analyses were performed for alemtuzumab, fingolimod, and natalizumab to test the robustness of the analyses to variations in underlying model assumptions or to the application of alternative grouped input parameters. The following scenarios were considered: the healthcare perspective (excluding both direct non-medical and indirect costs), alternative time horizons (20 and 80 years), and changing the discontinuation probability. In addition, mortality was modeled using the EDSS-specific standardized mortality ratio (SMR) instead of a fixed SMR for MS. Another scenario analysis was run, setting caregiver disutility to zero. Lastly, different waning effect scenarios were conducted for both the HDA and RES subpopulation to analyze the influence of different waning effects of cladribine tablets. Three approaches were considered:

1. Cladribine effect was gradually waned to 0% after year 6 (assuming full effect until year 2, 75% effect until year 4, and 50% effect until year 6).

2. Comparator effect was gradually waned to 0% after year 6, keeping cladribine tablets waning the same as the base case.

3. Both cladribine tablets and the comparator effect were gradually waned to 0% after year 6.

Lastly, a scenario analysis was included using data from the BCMS registry [21] for both RRMS and SPMS inputs instead of using BCSM registry data for RRMS and the London Ontario Registry [23] data for SPMS.

Probabilistic sensitivity analyses (PSA) were also performed to assess the variation in results stemming from the combined uncertainty in each individual model parameter (Table 9). The input variation per input parameter is provided in the Supplementary Appendix. Finally, a value-of-information (VOI) analysis was conducted, in line with Dutch health economic guidelines [17]. VOI analysis quantifies the value brought by reducing decision uncertainty by means of collecting additional information [46].

Table 9.

Distributions used for classes of parameters in PSA

Input	PSA distribution
Baseline age	Log-normal
Baseline weight distribution	Dirichlet
Baseline EDSS distribution	Dirichlet
Health state utility	Log-normal
Disutilities	Normal
AE probabilities	Beta
Discontinuation probabilities	Beta
Baseline relapse rate	Log-normal
Annual reduction in relapse rate	Beta
ARR rate ratio	Log-normal
Duration of relapse	Log-normal
6M-CDP log hazard ratio	Normal
HDA/RES progression adjustment factor	Log-normal
SMR	Log-normal
Time to SPMS	Multivariate normal
Costs	Gamma

PSA probabilistic sensitivity analysis, EDSS Expanded Disability Scale, AE adverse event, ARR annualized rate, HDA high disease activity, RES rapidly evolving severe, SPMS secondary progressive multiple sclerosis, SMR standardized mortality ratio, 6M-CDP 6-month confirmed disability progression

The VOI analysis results are expressed in the population expected value of perfect information (PEVPI), which expresses the value of information considering the number of times the decision has to be made over the lifetime of the technology. Thus, the PEVPI depends on the number of patients who will be treated with cladribine tablets, accounting for the incidence of the decision. In technical terms, based on the PSA outcomes, a per-patient EVPI is calculated as the average of the opportunity losses of all PSA outcomes. This per-patient EVPI is scaled up to a population level EVPI (PEVPI) in order to make it relevant to the decision regarding additional research, using Eq. 1 below, where ‘N_i’ denotes the relevant number of patients, ‘T’ denotes the effective lifetime (in years) for the new product, and ‘a’ denotes the discount rate.

$$\text{PEVPI}=\text{EVPI}\times \sum _{i=1}^T\frac{N_i}{{(1+a)}^i}$$ 1

Results

Base-Case Scenario

An overview of the results of the base-case analyses is given in Table 10, while a breakdown of discounted costs is given in Table 11. In the HDA subpopulation, cladribine tablets were the cost-effective (dominant) option compared with alemtuzumab and fingolimod, and also compared with natalizumab in the RES subpopulation. Outcomes are primarily driven by the lower drug cost of cladribine tablets and direct non-medical costs (especially versus fingolimod) rather than differences in efficacy.

Table 10.

Results from the base-case analysis

HDA population	Cladribine tablets	Alemtuzumab	Fingolimod
Total costs	€1,365,355	€1,371,105	€1,467,052
Incremental costs (compared with cladribine tablets)	–	− €5939	− €101,887
Total QALYs	9.318	9.219	8.333
Incremental QALY (compared with cladribine tablets)	–	0.099	0.985
ICER (compared with cladribine tablets)	–	Dominant	Dominant
NMB	–	€10,866	€151,115

RES population	Cladribine tablets	Natalizumab
Total costs	€1,436,038	€1,527,896
Incremental costs (compared with cladribine tablets)	–	− €91,858
Total QALYs	9.417	8.794
Incremental QALY (compared with cladribine tablets)	–	0.623
ICER (compared with cladribine tablets)	–	Dominant
NMB	–	€122,986

HDA high disease activity, QALYs quality-adjusted life-years, ICER incremental cost-effectiveness ratio, NMB net monetary benefit, RES rapidly evolving severe

Table 11.

Breakdown of costs (discounted)

HDA population	Cladribine tablets (€)	Alemtuzumab (€)	Fingolimod (€)
Drug cost	64,839	65,496	107,311
Adverse event cost	366	438	374
Relapse and rescue cost	3968	3739	4154
Direct medical and non-medical costs	744,013	748,034	786,526
Indirect cost	551,794	553,421	568,675
Total cost	1,365,165	1,371,105	1,467,052

RES population	Cladribine tablets	Natalizumab
Drug cost	63,882	101,572
Adverse event cost	366	327
Relapse and rescue cost	5851	5927
Direct medical and non-medical costs	789,201	814,243
Indirect cost	575,951	585,741
Total cost	1,436,038	1,527,896

HDA high disease activity, RES rapidly evolving severe

Sensitivity Analyses

Deterministic Sensitivity Analysis

A deterministic sensitivity analysis (DSA) was performed with a threshold of €50,000/QALY for both the HDA and RES subpopulations (Figs. 2, 3, 4). For all populations, the parameters that exhibited the greatest influence on the base-case results were confirmed disability progression (for cladribine tablets, alemtuzumab, fingolimod and natalizumab) and cost discounting. Importantly, the sensitivity analyses showed that the model is extremely sensitive to the variability in efficacy in terms of disease progression of the drugs.

Fig. 2.

Tornado diagram around net monetary benefit (cladribine tablets vs. alemtuzumab)

Fig. 3.

Tornado diagram around net monetary benefit (cladribine vs. fingolimod)

Fig. 4.

Tornado diagram around net monetary benefit (cladribine vs. natalizumab)

Structural Sensitivity Analysis

Cladribine tablets remained cost effective (dominant) in all structural sensitivity scenarios considered in the HDA population, and remained the cost-effective (dominant) approach for all waning effect scenarios in the HDA population. In the RES population (versus natalizumab) cladribine remained cost effective (dominant) or was less costly and less effective. An overview of the structural sensitivity analyses performed in the model is presented in Table 12.

Table 12.

Overview of structural sensitivity analyses performed in the model

	vs. alemtuzumab	vs. fingolimod	vs. natalizumab
Healthcare perspective	Cladribine dominant	Cladribine dominant	Cladribine dominant
Time horizon of 20 years	Cladribine dominant	Cladribine dominant	Cladribine dominant
Time horizon of 80 years	Cladribine dominant	Cladribine dominant	Cladribine dominant
Alternative discontinuation probability	Cladribine dominant	Cladribine dominant	Cladribine dominant
Mortality modeled using EDSS-specific SMRs	Cladribine dominant	Cladribine dominant	Cladribine dominant
Caregiver disutility set to zero	Cladribine dominant	Cladribine dominant	Cladribine dominant
Cladribine effect was gradually waned to 0% after year 6 (assuming full effect until year 2, 75% effect until year 4, and 50% effect until year 6)	Cladribine dominant	Cladribine dominant	Cladribine less costly and less effective
Comparator effect was gradually waned to 0% after year 6, continually waning cladribine tablets the same as the base case	Cladribine dominant	Cladribine dominant	Cladribine dominant
Both cladribine tablets and comparator effect were gradually waned to 0% after year 6	Cladribine dominant	Cladribine dominant	Cladribine less costly and less effective
Using data from the study by Palace et al. [21] for both the RRMS and SPMS inputs	Cladribine dominant	Cladribine dominant	Cladribine dominant

SPMS secondary progressive multiple sclerosis, SMR standardized mortality ratio, EDSS Expanded Disability Scale, RRMS relapsing–remitting multiple sclerosis

Probabilistic Sensitivity Analysis

The outcomes of the PSA showed that for the HDA population, cladribine tablets were the cost-effective (dominant) strategy when compared with alemtuzumab in 50.9% of iterations, at a threshold of €50,000/QALY gained (Fig. 5 ). Half (47%) of the iterations were in the south-east quadrant, and half (47%) were in the north-west quadrant. This reflects the uncertainty around the base-case results, and, as such, cladribine tablets should be considered at parity with alemtuzumab. When compared with fingolimod, cladribine tablets were the cost-effective (dominant) strategy, with a 98.2% probability of being cost effective at a threshold of €50,000/QALY gained (Fig. 6). Almost all iterations were in the south-east quadrant, indicating the robustness of the analysis. For the RES population, when comparing against natalizumab, cladribine tablets were the cost-effective (dominant) strategy, with a 94.1% probability of being cost effective at a threshold of €50,000/QALY gained (Fig. 7).

Fig. 5.

Cladribine tablets vs. alemtuzumab (high disease activity population)

Fig. 6.

Cladribine tablets vs. fingolimod (high disease activity population)

Fig. 7.

Cladribine tablets vs. natalizumab (RES population)

Value-of-Information Analysis

The number of patients eligible for treatment with cladribine tablets in The Netherlands was estimated at 383, based on the Dutch population [47] and MS prevalence in Flanders, Belgium [48]. Uptake was estimated at 30%, which is the expected market share in the first year, as verified by the Dutch Healthcare Institute (Zorginstituut Nederland), resulting in a PEVPI of €19,295,441. Given the high impact that the estimated uptake has on the calculation of the PEVPI, alternative values for the uptake were explored. The different uptake scenarios give the following outcomes: using an uptake of 10% (38 patients treated in The Netherlands), the PEVPI was estimated to be €6,431,814; with an uptake of 20% (77 patients), the PEVPI was €12,863,627; and with a 50% uptake, the PEVPI amounted to €32,159,068

Discussion

This paper reports on the cost effectiveness, from the Dutch context, of cladribine tablets versus alemtuzumab and fingolimod in the RRMS HDA patient population, and versus natalizumab in the RRMS RES subpopulation. It details a comparison between the costs and effects of the alternative treatments using a cohort-based, multi-state Markov transition model. The choice of this model is in accordance with the majority of models used in economic analyses of cost effectiveness of disease-modifying therapies in MS. More specifically, 24 of 33 studies included in the systematic literature review of Iannazzo et al. used the Markov transition model [49]. The model was based on a previously constructed UK model that used 11 health states [13], thus assuming no differences in progression rates and quality of life between patients in RRMS or SMPS. In the current model, a 21-health-state structure was applied that does allow differences between RRMS and SMPS. Applying this 21-state model was based on the recommendation and opinion of the Dutch KOL.

The results of the base-case analysis demonstrated that cladribine tablets were cost effective versus alemtuzumab and fingolimod in the HDA patient population, and versus natalizumab in the RES patient population, at a willingness-to-pay threshold of €50,000. It seems that this is largely attributable to the lower cost of cladribine tablets. The treatment of RRMS in the HDA subgroup has the potential to provide significant cost savings when used instead of alemtuzumab and fingolimod, with an NMB of €10,866 and €151,115, respectively. In addition, the treatment of RES RRMS with cladribine tablets instead of natalizumab in this subgroup has the potential to provide cost savings, with an NMB of €122,986. The DSAs demonstrated that the evaluation is extremely sensitive to treatment effect on confirmed disability progression in both scenarios, which shows that there is strong uncertainty around the relative effectiveness. The PSA for both scenarios (HDA and RES subpopulations) showed significant overlap in the credible intervals for total lifetime QALY outcomes and costs for cladribine tablets and all relevant comparators, which further highlights the uncertainty present. The probability that cladribine tablets are a cost-effective treatment option for HDA patients compared with alemtuzumab and fingolimod was 50.9% and 98.2%, respectively, and 94.1% for RES patients compared with natalizumab. Note that the PSA outcomes against alemtuzumab demonstrated considerable uncertainty. Overall, 47% of iterations were in the north-west quadrant, i.e. dominated, and 47% were in the south-east quadrant, i.e. dominant. The results of the PSA indicate that despite the dominance of cladribine in the base-case, these treatments (cladribine tablets and alemtuzumab) should be considered at parity.

Our results are in line with findings of other researchers suggesting that cladribine is cost effective for the treatment of HDA RRMS patients, and is therefore recommended for reimbursement. In England, cladribine tablets were dominant versus alemtuzumab and natalizumab in pairwise comparisons. Cladribine tablets had a 93% probability of being cost effective at a threshold of ₤30,000/QALY gained [13]. In Bulgaria, cladribine tablets were considered a cost-effective therapeutic option compared with alemtuzumab (incremental cost-effectiveness ratio = Bulgarian Lev 663.03/QALY) [50]. The cost effectiveness of cladribine for the treatment of adult patients with HDA RRMS, defined by clinical or imaging features, also suggested that cladribine is considered cost effective. Cladribine was cost saving versus all alternative strategies, with incremental costs ranging from − €60,604 (alemtuzumab) to − €176,902 (natalizumab) [51].

There are some limitations regarding the analyses conducted. The PSA for both scenarios (HDA and RES subpopulations) showed significant overlap in the credible intervals for total lifetime QALY outcomes and costs for cladribine tablets and all relevant comparators, which highlights the uncertainty present. Another important limitation is that there is a serious lack of head-to-head trials in the disease area of MS. All efficacy comparisons in the model are therefore based on NMA and meta-regression. In addition, the analyses in the HDA and RES populations consisted of post hoc, subgroup analysis. The intention-to-treat population of the CLARITY studies consisted of RRMS patients and was not restricted to patients with HDA or RES. These post hoc analyses were requested by the EMA, although they are an important additional source of uncertainty. In addition, some health technology assessment (HTA) agencies were critical about the network meta-regression approach (NICE and the Scottish Medicine Consortium [SMC]). The NICE committee concluded that even though there is not enough evidence to determine whether cladribine is more or less effective than other treatments, it is cost effective compared with all other treatments and was therefore recommended [52]. Additionally, despite their criticism regarding the indirect comparison, the SMC concluded that “the economic case has been demonstrated” [53]. Outside of the UK assessments, other HTA bodies accepted this approach, such as the European Network for Health Technology Assessment [54], the National Centre for Pharmacoeconomics (NCPE) in the Republic of Ireland [51], and the Tandvårds-Läkemedelförmånsverket (TLV) in Sweden [55], and concluded that cladribine is cost effective compared with the alternative options. Nevertheless, given these serious limitations and the strong uncertainty, all outcomes presented in this paper should be interpreted with caution. To limit the complexity of the model, it was assumed that patients received no further DMD treatment after cessation of therapy. However, this may not reflect current clinical practice and is a well-known limitation of MS models. Moreover, the model was constructed based on clinical efficacy and safety data from clinical trials that differ in many aspects, including study design, population characteristics, and the long time frame over which the data were collected (1990s to 2012). All scenario analyses performed are subject to the limited availability of 6-month confirmed disability progression data for comparator therapies.

A key strength of this study is that the model considers cost effectiveness across two subpopulations of MS. Moreover, the study included a VOI analysis quantifying the value of reducing uncertainty in the model. In addition, several relevant scenario analyses were conducted, including a waning effect scenario analysis.

Conclusions

The treatment of RRMS patients with cladribine tablets seems cost effective versus alemtuzumab and fingolimod in HDA patients, and versus natalizumab in RES patients, at a threshold of €50,000/QALY gained. Driven by the lower costs, cladribine tablets were cost effective (dominant) in all base-case analyses. Nevertheless, given that outcomes are based on indirect comparisons and post hoc subgroup analysis, and the considerable uncertainty surrounding the outcomes, the results presented in this paper should be interpreted with caution.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Author contributions

SB was responsible for development of the global cost-effectiveness model and contributed to the design of the Dutch model adaptation. MDF and KM contributed to the Dutch model adaptation. REM provided support in the model study design and writing of the manuscript. GJDH contributed to the model design and study design, and supported the writing of the manuscript. KMH Schiffers and GH contributed to the overall study design and supported the writing of the manuscript. MK was the overall guarantor of the study. All authors reviewed and approved the manuscript.

Compliance with Ethical Standards

Funding

Merck B.V., The Netherlands, provided funding to IQVIA for data acquisition and analysis.

Conflict of interest

Marieke Krol is a former employee, and Krijn M. H. Schiffers is a current employee, of Merck B.V., Schiphol-Rijk, The Netherlands, an affiliate of Merck KGaA, Darmstadt, Germany. Gerard Harty is an employee of EMD Serono, Inc., a business of Merck KGaA Darmstadt, Germany. Maria de Fransesco, Koshu Mahajan, Renée Else Michels, Gerald J. D. Hengstman, and Sangeeta Budhia report no further conflicts of interest.

Data availability statement

The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.